Figure 1

AT-MSC coinjection with high melanoma cell dose changes the time of xenograft onset and growth. A.-B. 20% AT-MSC co-administered s.c. with 1 × 10⁶ M4Beu significantly shortened time to 100% tumor onset from day 19 (control) to day 12, but did not significantly increase tumor burden. C.-D. 10% or 20% AT-MSC admixed with 1.5 × 10⁶ A375 melanoma cells also shortened time of xenograft onset and increased tumor burden in nude mice.